Idorsia Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning, and good afternoon. I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, at the JPMorgan conference, I've got the pleasure of introducing the Idorsia presentation and Q&A. Exciting times with the recent daridorexant approval announcement and ready for launch. So Idorsia's CEO, Jean-Paul Clozel, will be joining us for 20 minutes presentation, and then we're going to go into 20 minutes of Q&A.
And with that said, thanks a lot for joining us today, Jean-Paul. Looking forward to the presentation.
Thank you, James. So good morning and good afternoon to everybody. As James has mentioned, very exciting time. And for Idorsia -- and Idorsia has made huge progress in 4.5 years, and I'd like to discuss that today with you. Of course, we are going to make forward-looking statements, and I want to be -- you should be aware of the risk of investing into Idorsia.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |